Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial
Auclin, Edouard (Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France)
André, Thierry ![Identificador ORCID](/img/uab/orcid.ico)
(Oncology Multidisciplinary Research Group (GERCOR))
Taieb, Julien (UMR-S 1147, INSERM)
Banzi, Maria (Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy)
Van Laethem, Jean-Luc (Université Libre de Bruxelles. Department of Gastroenterology and Digestive diseases, Hopital Erasme)
Tabernero, Josep ![Identificador ORCID](/img/uab/orcid.ico)
(Vall d'Hebron Institut d'Oncologia)
Hickish, Tamas (Royal Bournemouth General Hospital (Dorset, Regne Unit))
de Gramont, Aimery (Institut Hospitalier Franco-Britannique. Department of Oncology)
Vernerey, Dewi (Oncology Multidisciplinary Research Group (GERCOR))
Universitat Autònoma de Barcelona
Data: |
2019 |
Resum: |
Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2. 35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. Prognostic and predictive values of post-operative CEA in patients with stage II CC were evaluated with Kaplan-Meier survival curves and Cox model with interaction terms. Disease-free survival (DFS) and overall survival (OS) were estimated. Among 899 stage II CC patients, post-operative CEA was available in 867 (96. 4%); and 434 (48. 65%) had a high-risk stage II disease. The 3-year DFS rate was 88. 5% and 78. 7% in the ≤ 2. 35 ng/mL and > 2. 35 ng/mL group, respectively (P = 0. 006). Use of oxaliplatin showed survival benefit only in patients with high-risk stage II CC and post-operative CEA > 2. 35 ng/ml (interaction term P = 0. 09 and 0. 03 for DFS and OS). CEA is a strong prognostic factor for DFS and OS in stage II CC. In the MOSAIC trial, only high-risk stage II CC patients with post-operative CEA > 2. 35 ng/mL benefited from the addition of oxaliplatin to LV5FU2. NCT00275210 (January 11, 2006). |
Drets: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ![Creative Commons](/img/licenses/by.ico) |
Llengua: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Matèria: |
Colorectal cancer ;
Colon cancer |
Publicat a: |
British journal of cancer, Vol. 121 (july 2019) , p. 312-317, ISSN 1532-1827 |
DOI: 10.1038/s41416-019-0521-7
PMID: 31296923
El registre apareix a les col·leccions:
Articles >
Articles de recercaArticles >
Articles publicats
Registre creat el 2021-04-13, darrera modificació el 2024-05-28